Adimab Provides 2022 Update on Clinical Pipeline
Retrieved on:
Wednesday, January 11, 2023
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Partner, G protein-coupled receptor, Control, Ion, Complex, Monoclonal antibody, Cytokine, Bispecific monoclonal antibody, HC, TCR International Series, ADC, Engineering, CAR, BLA, Therapy, FC, CD3, Antibody, Melinda Gates, Nextpoint, Bill & Melinda Gates Foundation, Immunoglobulin G, Top of the Form (quiz show), Bristol Myers Squibb, Sintilimab, Vaccine, Biotechnology Innovation Organization
This brings the total number of Adimab partner programs that have entered the clinic to 62.
Key Points:
- This brings the total number of Adimab partner programs that have entered the clinic to 62.
- Partners have recently filed for BLA approval on three additional programs and another three programs are currently in pivotal trials.
- “Over the last five years alone, partners have initiated clinical trials for 52 new programs.
- Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.